AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20614235
Drug: EEG Biofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EEG Biofeedback (Neurofeedback‐NFB) treatment, 20 sessions over 4 weeks
Trial: 20614235
Drug: Escitalopram treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram treatment, 10 mg per day for 8 weeks
Trial: 20614235
Drug: EEG Biofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EEG Biofeedback (Neurofeedback‐NFB) treatment
Trial: 3304367
Drug: Nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 20 mg three times a day
Trial: 6412224
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nifedipine and atenolol
Trial: 19788364
Drug: Systemic estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic estrogen therapy
Trial: 27982198
Drug: LT4/LT3 therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LT4/LT3 therapy (75/15 μg/day)
Trial: 27982198
Drug: LT4 treatment
RxNorm normalized name: LT4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LT4 treatment (125 or 150 μg/day)
Trial: 26585192
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g oral azithromycin
Trial: 18184245
Drug: Morphine 25
RxNorm normalized name: apomorphine 25 mg sublingual film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 25 microg.kg(‐1) in 2% lidocaine hydrochloride with 1 : 1 00 000 epinephrine
Trial: 11092066
Drug: 21 mg/24-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 mg/24-hour patch
Trial: 11092066
Drug: 15 mg/16-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/16-hour patch
Trial: 1592965
Drug: Brushing frequency
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brushing frequency twice per day
Trial: 23837551
Drug: cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cognitive behavioral therapy (15 sessions)
Trial: 20228986
Drug: G1 (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G1 (control group with orientation regarding oral hygiene)
Trial: 18544018
Drug: Antiretroviral drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral drugs (ARVs)
Trial: 16185306
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 10 mg kg(‐1) die(‐1) for 30 days
Trial: 15321815
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Fe (Fe group)
Trial: 15321815
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Zn (Zn group)
Trial: 12663287
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Fe + 10 mg Zn (Fe+Zn group)
Trial: 11573726
Drug: Transcatheter arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter arterial infusion with 5‐fluorouracil/doxorubicin
Trial: 11573726
Drug: Transcatheter arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter arterial infusion
Trial: 30915991
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg PF‐06372865
Trial: 30915991
Drug: 65 mg
RxNorm normalized name: opium 65 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 65 mg PF‐06372865
Trial: 27025186
Drug: Cediranib 20
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib 20 mg once-daily alongside chemotherapy then cediranib 20 mg once-daily maintenance (arm C)
Trial: 27025186
Drug: Placebo alongside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo alongside chemotherapy then placebo only maintenance (arm A)
Trial: 27025186
Drug: Cediranib 20
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib 20 mg once-daily alongside chemotherapy then placebo only maintenance (arm B)
Trial: 20194414
Drug: Social recovery‐focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social recovery‐focused cognitive‐behavioral therapy (SRCBT)
Trial: 12631309
Drug: Community-based Directly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based Directly Observed Treatment (CBDOT)
Trial: 12631309
Drug: Institutional-based Directly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Institutional-based Directly Observed Treatment (IBDOT)
Trial: 10839907
Drug: 0.1% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% ropivacaine and 0.5 microg/ml sufentanil
Trial: 10839907
Drug: 0.1% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% bupivacaine and 0.5 microg/ml sufentanil
Trial: 12053678
Drug: Intracoronary radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary radiotherapy with a prescribed dose of 17 Gy delivered via a Re‐188 filled balloon catheter.
Trial: 7641968
Drug: Intravenous sulprostone
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous sulprostone after cervical priming with dinoprostone
Trial: 7641968
Drug: Intramuscular sulprostone
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular sulprostone only
Trial: 7641968
Drug: Intravenous sulprostone
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous sulprostone only
Trial: 21481708
Drug: Cytomegalovirus glycoprotein-B
RxNorm normalized name: cytomegalovirus immunoglobulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant
Trial: 15312255
Drug: sCT 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sCT 1.0 mg (daily)
Trial: 15312255
Drug: sCT (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sCT (various doses)
Trial: 11340522
Drug: Poorly absorbable
RxNorm normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poorly absorbable antifungal agents
Trial: 11340522
Drug: Absorbable antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absorbable antifungal agents
Trial: 11340522
Drug: No antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antifungal prophylaxis
Trial: 1378156
Drug: Carvedilol 25
RxNorm normalized name: carvedilol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 25 mg once daily
Trial: 17288679
Drug: Losartan-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan-based therapy
Trial: 20583956
Drug: Moxifloxacin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin monotherapy
Trial: 18074762
Drug: Test fixed
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test fixed dose combination of nitazoxanide 500 mg and ofloxacin 200 mg
Trial: 18074762
Drug: Reference fixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference fixed dose combination of nitazoxanide 500 mg and ofloxacin 200 mg
Trial: 15821687
Drug: 0.4% stannous
RxNorm normalized name: Stanimax 0.4% Stannous Fluoride Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% stannous fluoride gel (SFG) for 4 minutes
Trial: 9972758
Drug: Epidural steroids
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural steroids administered with fluoroscopic guidance
Trial: 9972758
Drug: Epidural steroids
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural steroids administered without fluoroscopic guidance
Trial: 2332096
Drug: Pulsatile glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pulsatile glucagon delivery (377 ng/min for 2 min followed by 11 min with no infusion)
Trial: 6996158
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of penicillins, probenecid, a sulphonamide and ornidazole (once-only administration)
Trial: 6996158
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of penicillins, probenecid, a sulphonamide and metronidazole
Trial: 30788788
Drug: Single-Strand Assembly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-Strand Assembly (SSA) methods for combinatorial pathway engineering; details on dosage and duration not available.
Trial: 30788788
Drug: Combinatorial multigene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combinatorial multigene pathway assembly scheme based on SSA and Golden Gate Assembly; details on dosage and duration not available.
Trial: 23652196
Drug: Pressure patching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure patching with ofloxacin ointment (patch group, PG)
Trial: 23652196
Drug: Ofloxacin ointment
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ofloxacin ointment alone (ointment group, OG)
Trial: 18201563
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg pravastatin/day
Trial: 8915127
Drug: Octreotide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (100 micrograms subcutaneously every 8 hours for a maximum of six doses)
Trial: 8915127
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard treatment with intravenous fluid replacement and antibiotic treatment)
Trial: 6882062
Drug: Praziquantel, single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel, single oral dose of 30 mg kg‐1
Trial: 31084635
Drug: Dynamic Interpersonal
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic Interpersonal Therapy (DIT), 16 sessions over approximately 5 months
Trial: 31084635
Drug: Low-Intensity Treatment
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Intensity Treatment (LIT), control intervention
Trial: 21463169
Drug: Dynamic Interpersonal
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic Interpersonal Therapy (DIT)
Trial: 28179351
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus S-1 chemotherapy
Trial: 19491035
Drug: In vivo
RxNorm normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vivo administration of diclofenac sodium pellets
Trial: 16307008
Drug: Dapoxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapoxetine 60 mg + Tadalafil 20 mg
Trial: 16307008
Drug: Dapoxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapoxetine 60 mg + Sildenafil 100 mg
Trial: 10903223
Drug: Regular use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular use of albuterol
Trial: 10903223
Drug: As-needed use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As-needed use of albuterol
Trial: 9068463
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg for 4 weeks followed by either lansoprazole 30 mg or 60 mg for another 4 weeks
Trial: 9068463
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg b.i.d. for 8 weeks
Trial: 8438610
Drug: Oral immunization
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunization with cholera toxin B-subunit
Trial: 3101242
Drug: Iron dextran
RxNorm normalized name: Iron Dextran
DrugBank: Iron Dextran (DB00893)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron dextran (3 ml intramuscular iron dextran)
Trial: 30049223
Drug: 35 mg
RxNorm normalized name: papain 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg of inhaled vaporized cannabis (18.2% Δ9‐tetrahydrocannabinol, <0.1% cannabidiol)
Trial: 30049223
Drug: 35 mg
RxNorm normalized name: papain 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg of placebo control cannabis (CTRL; 0.33% Δ9‐tetrahydrocannabinol, <0.99% cannabidiol)
Trial: 23795576
Drug: VAL/HCT fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAL/HCT fixed-dose combination (FDC) tablet
Trial: 23795576
Drug: VAL +
RxNorm normalized name: Val
DrugBank: Valine (DB00161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VAL + HCT (concomitant administration)
Trial: 21091293
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g chicory native inulin
Trial: 18364345
Drug: Internet-administered measures
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-administered measures
Trial: 18364345
Drug: Telephone-administered measures
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered measures
Trial: 16263174
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of latanoprost and timolol once daily in the evening
Trial: 16263174
Drug: Unfixed combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfixed combination of latanoprost once daily in the evening and timolol in the morning and evening
Trial: 10576171
Drug: Phase 1
RxNorm normalized name: Coxiella burnetii phase 1 IgA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1 treatment
Trial: 10576171
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no phase 1 treatment)
Trial: 6452796
Drug: Zimelidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zimelidine (300 mg)
Trial: 26894169
Drug: Aprotinin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (1 ml of 10,000 Kallikrein Inactivator Units sub‐mucosally injected)
Trial: 26894169
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline (1 ml injected as control)
Trial: 24245554
Drug: Ethinyl estradiol
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ethinyl estradiol 0.03 mg/drospirenone (group 1)
Trial: 15774256
Drug: OM-89 (immunotherapeutic);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OM-89 (immunotherapeutic); 1 capsule per day for 90 days, followed by 3 months without treatment, then 10 days in Months 7, 8, and 9.
Trial: 15774256
Drug: Placebo; 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo; 1 capsule per day for 90 days, followed by 3 months without treatment, then 10 days in Months 7, 8, and 9.
Trial: 10099066
Drug: Claritin‐D 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Claritin‐D 24 Hour (loratadine 10 mg and pseudoephedrine sulfate 240 mg)
Trial: 10099066
Drug: Claritin‐D 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Claritin‐D 12 Hour (loratadine 5 mg and pseudoephedrine sulfate 120 mg)
Trial: 341283
Drug: Iron-dextran (Total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-dextran (Total Dose Infusion)
Trial: 26194125
Drug: Benachio Q
RxNorm normalized name: Chew Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benachio Q solution®
Trial: 23040887
Drug: Mepolizumab (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab (750 mg)
Trial: 12687836
Drug: Bepridil, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepridil, 200 mg/day (n = 14)
Trial: 12687836
Drug: Class Ic
RxNorm normalized name: Antiarrhythmics, class Ic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Class Ic antiarrhythmic drugs (Flecainide, 100 to 200 mg/day (n = 15) or Pilsicainide, 75 to 150 mg/day (n = 23))
Trial: 12687836
Drug: Class Ic
RxNorm normalized name: Antiarrhythmics, class Ic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Class Ic antiarrhythmic drugs
Trial: 8388332
Drug: Moderate-dose fentanyl
RxNorm normalized name: fentanyl Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dose fentanyl
Trial: 8388332
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of acupuncture and TES with moderate-dose fentanyl
Trial: 3812308
Drug: Propranolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (mean 371 mg)
Trial: 3812308
Drug: Diltiazem (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (mean 307 mg)
Trial: 2774228
Drug: Oral transmucosal
RxNorm normalized name: Thrive, 2 mg oral transmucosal gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmucosal fentanyl citrate (OTFC) 15-20 micrograms/kg (group B)
Trial: 2774228
Drug: Oral transmucosal
RxNorm normalized name: Thrive, 2 mg oral transmucosal gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmucosal fentanyl citrate (OTFC) (group B)
Trial: 25222800
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy for insomnia (CBTI‐BP; n = 17)
Trial: 19709502
Drug: 1 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/d of eicosapentaenoic acid (EPA) for 8 weeks
Trial: 10571599
Drug: SB-207266-A (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-207266-A (20 mg)
Trial: 8768852
Drug: Propranolol (10(‐4)
RxNorm normalized name: propranolol hydrochloride 4 MG/ML
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol (10(‐4) mol/L)
Trial: 8768852
Drug: Phentolamine (10(‐4)
RxNorm normalized name: phentolamine 10 MG/ML
DrugBank: Phentolamine (DB00692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phentolamine (10(‐4) mol/L)
Trial: 24244335
Drug: Durable polymer
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durable polymer drug-eluting stents (DES)
Trial: 22111914
Drug: Laparoscopic surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic surgery with fast track perioperative treatment and Xelox chemotherapy
Trial: 22111914
Drug: Open surgery
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open surgery with fast track perioperative treatment and Xelox chemotherapy
Trial: 22111914
Drug: Laparoscopic surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic surgery with conventional perioperative treatment and mFolfox6 chemotherapy
Trial: 22111914
Drug: Open surgery
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open surgery with conventional perioperative treatment and mFolfox6 chemotherapy
Trial: 19395457
Drug: Atacicept (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atacicept (single dose: 3, 9 or 18 mg/kg; or multiple dose: 2 x 9 mg/kg)
Trial: 16467018
Drug: Etanercept 25
RxNorm normalized name: etanercept 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 25 mg or 50 mg twice weekly (BIW) or 25 mg once weekly
Trial: 16467018
Drug: Placebo (original
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (original placebo patients received 25 mg BIW for the final 12 weeks of the double‐blind period)
Trial: 14748943
Drug: Micronised, dispersible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronised, dispersible ferric pyrophosphate (5 mg Fe) in infant cereal
Trial: 14748943
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate (5 mg Fe) in infant cereal
Trial: 14748943
Drug: Micronised, dispersible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronised, dispersible ferric pyrophosphate (5 mg Fe) in yoghurt drink
Trial: 14748943
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate (5 mg Fe) in yoghurt drink
Trial: 9369270
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 5.0 ng Ang II x kg(‐1) x min(‐1) (pressor dose)
Trial: 9369270
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 1.0 ng Ang II x kg(‐1) x min(‐1) (subpressor dose)
Trial: 9369270
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of Ang II during oral glucose tolerance test
Trial: 3883177
Drug: Intramuscular benzathine
RxNorm normalized name: Cephapirin Benzathine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular benzathine penicillin 2.4 million U weekly for three weeks (total 7.2 million U)
Trial: 3883177
Drug: Intravenous penicillin
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous penicillin G 20 million U a day for 10 days